Clearwater Analytics (NYSE: CWAN) announced today its agreement to acquire Enfusion, Inc. (NYSE: ENFN) for $1.5 billion, marking a significant move to create an integrated front-to-back investment management platform. The deal, announced January 13, 2025, will see Clearwater pay $11.25 per share in a mixed cash-and-stock transaction, along with $30 million to terminate Enfusion’s tax receivable agreement.
The acquisition brings together two complementary SaaS providers in the investment management space. Clearwater, known for its middle and back-office solutions, will integrate Enfusion’s front-office capabilities, including investment book of record (IBOR) and portfolio management systems, to create a unified cloud-native platform serving institutional investors.
“Today’s announcement is about creating a future where our clients benefit from the synergy of two highly complementary, innovative software leaders,” said Sandeep Sahai, CEO of Clearwater Analytics. The combination aims to eliminate the error-prone data handoffs that typically occur between front, middle, and back offices in investment operations.
The strategic merger significantly expands Clearwater’s market presence, particularly in the hedge fund sector where Enfusion has established itself as a leading platform provider. The deal is expected to increase Clearwater’s total addressable market by $1.9 billion and strengthen its international footprint, leveraging Enfusion’s strong presence in Europe and Asia, where it generates 38% of its revenue.
Clearwater expects to achieve substantial operational synergies, targeting $20 million in cost savings within the first two and a half years post-closing. The company also projects significant improvements in Enfusion’s adjusted EBITDA margins, anticipating a 400 basis point expansion in the first year and an additional 400 basis points in the second year after closing.
The transaction terms offer Enfusion shareholders $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock, representing a 13% premium over Enfusion’s January 10 closing price and a 32% premium over its September 19, 2024 price, before market speculation about a potential sale began.
Enfusion’s CEO Oleg Movchan expressed enthusiasm about the merger, stating, “Together with Clearwater, our shared passion for building innovative technologies and enriching every aspect of the client journey will now accelerate and enhance our combined ability to support our clients’ evolving needs.”
The deal has received unanimous approval from both companies’ boards of directors and a special committee of independent Enfusion directors. Major Enfusion shareholders, including FTV, ICONIQ, and Mr. Movchan, who collectively hold approximately 45% of voting power, have agreed to support the transaction.
Clearwater has secured $800 million in committed financing through a Term Loan B, along with a $200 million revolving credit line to support the transaction. The company expects to close the deal in the second quarter of 2025, subject to regulatory approvals and customary closing conditions. Upon completion, the combined entity will be positioned to offer a comprehensive, cloud-native investment management solution that serves clients across the entire investment lifecycle.
